Top Page
CVS Group plc
(LSE:CVSG)
CVS Group plc (CVSG) vs. iShares MSCI United Kingdom ETF (EWC)
CVS Group plc Business Overview & Revenue Model
CVS Group plc Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 659.20M | 647.30M | 608.30M | 554.20M | 510.10M | 427.80M |
| Gross Profit | 259.70M | 277.90M | 262.30M | 239.10M | 221.90M | 170.10M |
| EBITDA | 112.50M | 108.40M | 118.80M | 90.40M | 88.20M | 64.90M |
| Net Income | 17.30M | 6.20M | 41.90M | 25.70M | 19.30M | 5.70M |
Balance Sheet | ||||||
| Total Assets | 696.20M | 690.00M | 572.30M | 518.20M | 484.50M | 464.30M |
| Cash, Cash Equivalents and Short-Term Investments | 11.60M | 16.50M | 21.50M | 49.00M | 33.70M | 21.50M |
| Total Debt | 295.50M | 287.80M | 199.10M | 188.80M | 182.70M | 182.20M |
| Total Liabilities | 434.80M | 429.50M | 315.30M | 300.80M | 293.40M | 297.70M |
| Stockholders Equity | 261.30M | 260.40M | 257.00M | 217.40M | 191.10M | 166.60M |
Cash Flow | ||||||
| Free Cash Flow | 29.30M | 24.70M | 38.80M | 51.00M | 43.60M | 65.20M |
| Operating Cash Flow | 66.70M | 67.80M | 84.50M | 75.50M | 60.20M | 77.60M |
| Investing Cash Flow | -100.40M | -140.50M | -99.90M | -45.10M | -35.40M | -19.60M |
| Financing Cash Flow | 13.50M | 68.30M | -12.10M | -15.10M | -12.60M | -49.00M |
CVS Group plc Technical Analysis
CVS Group plc Peers Comparison
CVS Group plc Corporate Events
CVS Group plc has announced the granting of option awards over 276,364 ordinary shares under its Long Term Incentive Plan 2025. These options, which include awards to key executives such as the CEO, CFO, and Chief Veterinary Officer, will vest in three years, contingent on meeting performance criteria related to earnings per share growth and total shareholder return. This move is likely to align the interests of the management with those of the shareholders, potentially enhancing the company’s operational performance and market positioning.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading UK veterinary services provider, announced that its total issued share capital as of 31 July 2025 consists of 71,740,229 ordinary shares, each carrying one voting right. This update is significant for shareholders as it affects the calculations required under the FCA’s Disclosure Guidance and Transparency Rules, impacting how they notify or change their interest in the company.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £9.40 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced a trading update for the financial year ending June 30, 2025, highlighting a 5.4% revenue growth to £673.2 million and an expected adjusted EBITDA of approximately £134 million, aligning with market consensus. The company continues to expand in Australia with several acquisitions, while its UK acquisition activities are on hold pending a CMA investigation. The divestment of its Crematoria operations has reduced net bank borrowings and provided capital for further investments. Despite softer market conditions in the UK, CVS remains optimistic about its long-term growth prospects, supported by a strong balance sheet and a growing pet population.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a UK-based company, has announced a change in the voting rights held by Octopus Investments Limited. The notification indicates that Octopus Investments Limited’s voting rights in CVS Group plc have decreased from 6.98% to 5.99%, which could impact the company’s governance and decision-making processes.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced that its CEO, Richard Fairman, has purchased 1,644 ordinary shares of the company, increasing his total shareholding to 79,751 shares, which accounts for 0.111% of the company’s total voting rights. This transaction, conducted on the London Stock Exchange, reflects Fairman’s confidence in the company’s future prospects and may positively influence stakeholder perception.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced a change in the voting rights held by Grandeur Peak Global Advisors, LLC, which has reduced its stake from 4.93% to 3.87%. This adjustment in holdings could influence the company’s shareholder dynamics and potentially impact its strategic decisions, reflecting a shift in investment focus by a significant shareholder.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading UK veterinary services provider, announced that as of 30 June 2025, its total issued share capital consists of 71,740,184 Ordinary Shares, each carrying one voting right. This update is crucial for shareholders to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules, impacting the company’s transparency and stakeholder engagement.
The most recent analyst rating on (GB:CVSG) stock is a Hold with a £1200.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has responded to the Competition and Markets Authority’s (CMA) decision to extend the deadline for its market investigation into the supply of veterinary services for household pets in the UK. CVS is actively engaging with the CMA, providing feedback on transparency measures and expressing concerns over potential constraints on clinical freedom. The company supports the CMA’s focus on transparency but cautions against remedies that could inadvertently affect animal welfare and consumer choice. CVS remains optimistic that the extension will lead to a more proportionate remedy package, while acknowledging the uncertainty it brings to stakeholders.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc announced that David Wilton, the Non-executive Chairman, has purchased 1,000 ordinary shares in the company, increasing his total shareholding to 10,000 shares, which represents 0.014% of the company’s total voting rights. This transaction, conducted on the London Stock Exchange, signifies a potential vote of confidence in the company’s future prospects by its leadership.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc, a leading veterinary services provider, announced that its total issued share capital consists of 71,740,184 Ordinary Shares, each carrying one voting right, as of May 30, 2025. This update is crucial for shareholders to determine their interests in accordance with the FCA’s Disclosure Guidance and Transparency Rules.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has finalized the sale of its Crematoria operations to Anima Care UK Limited for £42.4 million, marking a strategic move to streamline its operations. This disposal is expected to result in a one-off profit of £32.0 million in its FY2025 accounts. Concurrently, CVS has expanded its presence in Australia by acquiring VPP Group PTY Ltd, adding six practice sites in Victoria, and now operates 28 practices across 42 sites in the country. These strategic decisions are likely to enhance CVS’s market positioning and operational focus.
The most recent analyst rating on (GB:CVSG) stock is a Buy with a £1500.00 price target. To see the full list of analyst forecasts on CVS Group plc stock, see the GB:CVSG Stock Forecast page.
CVS Group plc has announced a change in its voting rights structure, with BlackRock, Inc. acquiring a significant stake. The notification indicates that BlackRock’s voting rights in CVS Group have increased to 5.02%, crossing the 5% threshold, which is a notable development for the company’s shareholder composition.